IV Secukinumab Trials Hit Primary Endpoints in PsA, AxSpA

Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy vs placebo in treating psoriatic arthritis and axial spondyloarthritis.

Related Keywords

New York ,United States ,Oregon ,Alanj Kivitz , ,Assessment Of The Spondyloarthritis International Society ,American College Of Rheumatology ,Clinical Research ,Altoona Center ,Oregon Health Science University ,Drug Administration ,American College ,Spondyloarthritis International Society ,Atul Deodhar ,Oregon Health ,Science University ,Psoriatic Arthritis ,Ankylosing Spondylitis ,Arthritis ,Oint Inflammation ,Biologic Therapy ,Hospitals ,Interleukins ,Intravenous Iv ,Intravenous ,Tv ,Practice Management ,Pain Management ,Back Pain ,Adherence ,Dherence To Medication Issues For Patients ,Blood ,Clinical Trials ,Linical Studies ,Insurance ,Medicare ,Monoclonal Antibody ,Etuximab ,Ituximab ,Inew Yo ,